Abstract : The outcomes of treatment for pain disorder are generally disappointing : symptoms are poorly controlled, they are seldom managed by experts, and they are often long standing. The aim of the present study was to compare the therapeutic effectiveness of paroxetine and milnacipran for outpatients with pain disorder. The study was performed on 43 consecutive outpatients with pain disorder diagnosed according to DSM-IV-TR criteria. Patients were treated with either antidepressant for 8 weeks. Pain was selfassessed using the Short-Form McGill Pain Questionnaire SF-MPQ , the total Pain Rating Index t-PRI , Present Pain Intensity PPI , and visual analogue scale VAS . In addition, pain was evaluated objectively using Pain Vision a machine devised by NIPRO for semiquantitative measurements . Possible depressive symptoms were rated on the Hamilton Depression Scale HAM-D and the Zung Self-rating Depression Scale SDS . Although VAS scores decreased signi cantly over the course of the 8-week trial in both the paroxetine-and milnacipran-treated groups from 6.6 2.3 to 4.8 3.0 P 0.01 and from 7.5 2.4 to 5.4 3.3 P 0.03 , respectively , the t-PRI decreased only in the paroxetine group from 13.9 10.1 to 7.6 7.5 ; P 0.01 . The Pain Vision indicated a tendency for decreased pain in both groups, with no significant differences between them. There were no significant changes in the SDS in either group, but the HAM-D decreased significantly in the milnacipran-treated group from 7.8 4.0 to 6.7 3.9 ; P 0.04 . The results of the present study suggest that both paroxetine a selective serotonin reuptake inhibitor and milnacipran a selective serotonin-noradrenaline reuptake inhibitor may decrease pain in individuals with pain disorder.
are seldom managed by experts, and they are often long standing. In addition, the risk of suicide is increased in patients with chronic pain 1 . Many different somatic and psychiatric diseases may cause chronic pain. The latter include depression and somatization, delusional, and anxiety disorders. The de nition of pain adopted by the International Association for the Study of Pain IASP is essentially that pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage 2 . From this viewpoint, pain is an emotional experience, and it is easy to understand why chronic pain coexists with psychiatric diseases and mood changes.
There are no therapeutic guidelines for the treatment of pain disorder. In general, analgesics have limited effectiveness and may lead to drug abuse and/or dependence. Therefore, tricyclic antidepressants TCAs are often used to treat pain disorders. However, because of psychological reasons, it is dif cult to evaluate pain accurately using subjective measures. Accordingly, objective or quanti ed evaluation of pain is warranted.
The Pain Vision is a machine produced by NIPRO Pain Vision PS-2100 that has been developed speci cally to provide a semiquantitative measure of pain.
The aim of the present study was to compare the therapeutic effectiveness of paroxetine and milnacipran for outpatients with pain disorder. Pain was evaluated both subjectively SF-MPQ and objectively Pain Vision .
Materials and Methods

Study subjects
The study subjects were selected from patients 20 years or older who regularly attended the psychiatry clinic at Showa University East Hospital. Exclusion criteria included pregnancy, thyroid gland malfunction, glaucoma, and urinary retention.
All participants were examined by a psychiatrist and had to ful ll the Diagnostic and Statistical Manual of Mental Disorders fourth edition, text revision ; DSM-IV-TR 13 criteria for pain disorder, namely pain disorder associated with psychological factors or pain disorder associated with psychological factors and general physical diseases.
Study design
Patients were allowed to continue analgesic and anti-in ammatory medications at the same dose during the pretreatment period, although they were not allowed to increase medication doses during the treatment period. Patients were allowed to take low doses of benzodiazepines for sleep disturbances, but were not allowed to take anti-anxiety agents for pain relief.
Patients were randomly assigned to receive either paroxetine or milnacipran for 8 weeks using random tables with the first and original generator 14 . The doses of paroxetine ranged from 10 to 40 mg/day, whereas those of milnacipran ranged from 50 to 150 mg/day.
The initial doses of paroxetine and milnacipran were 10 and 50 mg, respectively, although these doses were suitably adjusted during the treatment period.
Assessments
Patients were evaluated at baseline and then again after 4 and 8 weeks treatment. Pain was self-assessed using the SF-MPQ, the total Pain Rating Index t-PRI , Present Pain
Intensity PPI , and using a visual analogue scale VAS . In addition, pain was evaluated objectively with the Pain Vision. By using electrode pads attached to the subject s arm and measuring the current perception threshold and the current corresponding to the pain, the Pain Vision enables the magnitude of the pain to be semiquanti ed. The index relating to the magnitude of pain is based on the Pain Index and Pain Frequency. Possible depressive symptoms were rated in each of the subjects using the Hamilton Depression Scale HAM-D and Zung Self-rating Depression Scale SDS .
All adverse events were recorded : those noted by psychiatrists during the treatment period and those of which the subjects complained. Newly expressed symptoms and symptoms that worsened during the treatment period were recorded as adverse events. If adverse events occurred, we recorded the symptoms, the severity of the symptoms, and the number of manifestations and took appropriate action.
The present study was performed in accordance with ethical guidelines and principles for clinical trials based on the Declaration of Helsinki. The study, including the risks and bene ts of participation, was fully explained to patients in a written document. Before enrolling in the study, patients were required to provide written informed consent.
Statistical analysis
All data were analyzed using SAS 9.1.3 and managed using PROMASYS . Ef cacy measures were analyzed in the intent-to-treat population, which was defined as patients who underwent the randomization process and took at least one dose of paroxetine or milnacipran and had at least one post-baseline ef cacy evaluation. Safety parameters were analyzed for all patients enrolled in the study who took at least one dose of study medication. If patients dropped out prematurely from the study or discontinued treatment, the last evaluation score of the day was treated as an evaluation score at 8 weeks using the Last Observation Carried Forward LOCF method.
Differences in demographic variables and clinical characteristics between the two treatment groups were assessed using Fisher s exact test for categorical variables and the t-test for continuous variables. The t-test was used to evaluate differences between baseline and the last evaluation score for the primary outcome variables t-PRI, VAS, PPI and the secondary outcome variables Pain Vision, HAM-D, SDS within each group. Two-sided P 0.05 was considered signi cant. Unless indicated otherwise, data are presented as the mean SD.
Results
In all, 43 patients, enrolled in the trial, were randomly divided into two groups. Twentyone patients were assigned to receive paroxetine and 22 were assigned to receive milnacipran. Eighteen patients were unable to complete the treatment period. Four patients were lost to follow-up at 4 weeks one in the paroxetine group and three in the milnacipran group . Twelve patients ve in the paroxetine group and seven in the milnacipran group dropped out because of adverse effects ; another two patients in the milnacipran group dropped out due to inef cacy of the medication. Accordingly, at the end of the treatment period, there were 15 patients remaining in the paroxetine group 10 men ; mean age 55.2
16.3 years and 10 patients remaining in the milnacipran group four men ; mean age 49.9 13.6 years . The demographic characteristics of all study subjects are given in Table 1 .
There was a signi cant decrease in t-PRI in the paroxetine-treated group at the end of the 8-week treatment period compared with baseline 7.6 7.5 vs. 13.9 10.1, respectively ; P 0.01 , but no signi cant change in t-PRI in the milnacipran-treated group 7.9 4.6 vs. 13.0 9.1, respectively ; P 0.11 ; Fig. 1 ; Table 2 . Pain scores on the VAS decreased signi cantly in both groups from 6.6 2.3 to 4.8 3.0 in the paroxetine-treated group P 0.01 ; and from 7.5 2.4 to 5.4 3.3 in the milnacipran-treated group P 0.03 . There was a tendency for PPI to decrease in both groups, but the differences failed to reach statistical signi cance from 2.7 1.2 to 1.9 1.3 in the paroxetine-treated group P 0.10 ; and from 3.0 1.3 to 2.1 0.9 in the milnacipran-treated group P 0.07 . When pain was evaluated semiquantitatively using the Pain Vision, no signi cant differences were observed between the two groups, although there were tendencies for decreases in the Pain Index and Pain Frequency in both groups following treatment. There were no signi cant changes in SDS in either group from 44.4 13.9 to 43.9 12.1 in the paroxetine-treated group P 0.86 ; and from 45.2 11.6 to 40.5 9.7 in the milnacipran-treated group P 0.11 , but HAM-D decreased signi cantly after treatment in the milnacipran-treated group from 7.8
4.0 to 6.7 3.9 ; P 0.04 ; Table 2 .
Seven patients one in the paroxetine group and six in the milnacipran group withdrew from treatment before the rst outcome assessment. Eleven patients ve in the paroxetine group and six in the milnacipran group withdrew from the study before the second outcome measurement. Table 3 lists adverse events. Most adverse events were mild to moderate in severity, and no patient experienced any serious adverse event. The most common adverse events were nausea, somnolence, and constipation.
Discussion
To the best of our knowledge, the present study is the rst to compare an SSRI with Fig. 1. Significant decreases were seen in the total Pain Rating Index t-PRI in the paroxetine-treated group over the course of the 8-week trial from 13.9 10.1 to 7.6 7.5 ; P 0.01 , but there was no significant change in the milnacipran-treated group from 13.0 9.1 to 7.9 4.6 ; P 0.11 . Data are the mean SD. P 0.05 compared with baseline values.
an SNRI for patients with pain disorder in the psychiatric setting. All participants in the present study were examined by a board psychiatrist and had to ful ll DSM-IV-TR criteria for pain disorder. In addition, pain was evaluated not only subjectively using the SF-MPQ and VAS, but also objectively using the Pain Vision. The results show that both paroxetine and milnacipran are bene cial in reducing pain. Although the VAS scores were signi cantly decreased over the course of the 8-week trial in both groups, t-PRI only decreased signicantly in the paroxetine-treated group.
Previous studies demonstrated that antidepressants that affect noradrenaline, such as TCAs and SNRIs, are more effective pain relievers than single-action serotonergic anti- There are several limitations to the present study. First, the sample size was small and the drop-out rate was high. Generally, high drop-out rates are common for pharmacological trials of somatoform disorders 17 because patients with somatization disorders, including pain disorders, are the most dif cult to treat, with the conditions being largely treatment resistant.
Further studies with a larger sample are needed to con rm the therapeutic effectiveness of paroxetine and milnacipran for pain disorder. Second, the dose of antidepressants used in the present study was not xed over the course of the 8-week trial, and the exible dosing of paroxetine and milnacipran may have affected the therapeutic effectiveness of the treatment regimen. Third, the present study focused only on paroxetine and milnacipran. There are many drugs in both the SSRI and SNRI categories, such as sertraline and s-citalopram SSRIs and duloxetine and venlafaxine SNRIs , and it is not clear whether these drugs are as effective as paroxetine and milnacipran. This issue should be explored in future studies.
In conclusion, the present study is the rst to compare the therapeutic effectiveness of paroxetine and milnacipran for pain disorder in a psychiatric setting. The main finding of the study is that both paroxetine and milnacipran are bene cial in reducing pain. Signi cant decreases were seen in t-PRI in the paroxetine group and in VAS scores in both groups during the trial. In contrast with previous studies, paroxetine, a single-action serotonergic drug, had the same pain-relieving effect as milnacipran, a dual-action serotonergic and noradrenergic drug. Despite the limitations of the present study, the results indicate that both the SSRI and SNRI could reduce pain in individuals with pain disorder.
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